menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeted Anticoagulants Move From Lab to Patient Trials

close
Targeted Anticoagulants Move From Lab to Patient Trials
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    Anticoagulants like heparin have been around for decades, but the drugs have drawbacks for many patients. Dr. Ted Love, Chief Executive of biotech company Nuvelo, tells host Bruce Japsen about targeted anticoagulant therapies that are being developed to be safer and more effective than the old standby heparin therapy and other blood treatments. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Anticoagulants like heparin have been around for decades, but the drugs have drawbacks for many patients. Dr. Ted Love, Chief Executive of biotech company Nuvelo, tells host Bruce Japsen about targeted anticoagulant therapies that are being developed to be safer and more effective than the old standby heparin therapy and other blood treatments. 

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 6/5/20